Blood pressure and dementia risk share surprising link, study suggests
In a large, randomized trial, researchers led by First Hospital of China Medical University discovered that "intensive blood pressure control" resulted in a 15% reduced dementia risk among participants and a 16% reduced risk of cognitive impairment.
The study included 33,995 people in rural China aged 40 or older who had "uncontrolled hypertension."
The participants were divided into two groups. One received "usual care," while the other was assigned to "trained non-physician community healthcare providers" who prescribed "titrated antihypertensive medications."
For the latter group, the medications helped them achieve a systolic blood pressure goal of <130 mm Hg and a diastolic blood pressure goal of <80 mm Hg, according to the study findings in Nature Medicine.
"The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group," the researchers wrote.
They were also less likely to experience "serious adverse events."
This was one of the first large-scale, randomized, controlled effectiveness trials to demonstrate a "significant reduction in all-cause dementia associated with lowering blood pressure," the researchers concluded.
There were some limitations of the study, the article acknowledged, including the absence of baseline and follow-up cognitive assessments.
Dr. Bradley Serwer, a cardiologist and chief medical officer at VitalSolution, a Cincinnati, Ohio-based company that offers cardiovascular and anesthesiology services to hospitals nationwide, said this study presents an "intriguing approach" to addressing dementia in individuals with uncontrolled hypertension.
"Unlike studies performed in the United States, this study employed non-physicians to significantly reduce blood pressure in rural China through a 'cluster' blinding method," Serwer, who was not involved in the study, told Fox News Digital.
"While the study can be subject to scrutiny, it raises a pertinent question: How crucial is modification of cardiovascular risk factors in the development of dementia?"
The primary medications used in the study to lower blood pressure were calcium channel blockers and angiotensin receptor blockers, Serwer noted.
"These commonly prescribed medications have been independently associated with a reduced risk of dementia, irrespective of the magnitude of blood pressure reduction they achieve," he said.
"This raises the possibility that the lower rates of dementia observed may be attributed to other beneficial effects of the medications rather than solely to blood pressure reduction."
To confirm the findings, Serwer said it would be beneficial to include baseline cognitive assessments of the patients and to identify the prevalence of Alzheimer's dementia within the communities.
"The most significant takeaway from this study is the profound importance of addressing blood pressure, cholesterol, smoking and sedentary lifestyles," the cardiologist said.
"By prioritizing these factors, we not only aim to prevent heart attacks and strokes, but also strive to enhance overall quality of life."
The study was supported by the National Key Research and Development Program of the Ministry of Science and Technology of China, Chinese Society of Cardiology Foundation, and the Science and Technology Program of Liaoning Province, China.
Fox News Digital reached out to the researchers for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
HealthPartners launches simple, copay-only health plan
BLOOMINGTON, Minn.--(BUSINESS WIRE)--HealthPartners is launching a variable copay benefit plan that aims to provide unparalleled transparency of cost and coverage to members. 'We developed Simplica in response to the growing demand for more predictable benefits.' -Andrea Walsh, HealthPartners president and CEO Share HealthPartners Simplica NextGen Copay health plan has no deductible or coinsurance for in-network care, and members see what they'll pay up front before scheduling. Copay amounts for specific services at each hospital or clinic vary based on the quality and affordability of the care delivered. A key feature of the plan is the personalized digital experience fully integrated within a member's HealthPartners account. Using HealthPartners' Find Care tool, members can search by condition, provider or service; compare care options; and see their exact copay before scheduling. Members pay less when they choose care with better outcomes. 'We developed Simplica in response to the growing demand for more predictable benefits,' says Andrea Walsh, HealthPartners president and CEO. 'This plan gives members the cost clarity and ease they expect from their health plan and guides them in making informed decisions about where to get the care they need.' For example, the copay for an office visit will range from $20 to $150 depending upon the plan option, care site and service. Most same day labs and x-rays are bundled into the copay – helping reduce unexpected costs. Services that may require a separate copay are also visible through the Find Care digital experience. In addition, many virtual care options are covered at a $0 copay. The plan will launch Jan. 1, 2026, and is initially available to large-group, self-insured employers in the Twin Cities metro and surrounding counties. Simplica can save companies up to 15% in claim costs and that translates into savings for employees. 'Unlike third-party platforms or standalone applications, Simplica delivers one seamless experience that makes it easier for members and employers to understand and manage costs,' says Moe Suleiman, HealthPartners senior vice president of health solutions. 'This plan ties copays to provider value, guides members in real time, and delivers the digital-first convenience today's workforce expects.' For more information, visit the Simplica NextGen Copay website. About HealthPartners HealthPartners is a nonprofit organization with a mission of improving health and well-being in partnership with its members, patients and community. An integrated system of care and coverage since its founding in 1957, HealthPartners operates hospitals and clinics, health plans, and a research and education institute. The Minneapolis-based organization serves more than 1.3 million patients in Minnesota and Wisconsin and 1.7 million medical and dental health plan members nationwide. For more information, visit
Yahoo
an hour ago
- Yahoo
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics' Casgevy holding a competitive edge over bluebird bio's Zynteglo as preferred beta thalassemia gene therapies. EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within the hematology community: whether the future belongs to gene editing or gene addition. Recent physician survey data from Market DynamixTM: Transfusion-Dependent Thalassemia reveal a clear shift in preference toward the CRISPR/Cas9-based therapy Casgevy with half of hematologists now favoring it, compared to just one-fifth for Zynteglo, a lentiviral vector-based therapy. The remaining respondents express no strong preference, citing similar efficacy and safety profiles in clinical trials. Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) uses CRISPR/Cas9 gene editing to disable the BCL11A enhancer, reactivating the body's natural production of fetal hemoglobin (HbF) – an oxygen-carrying molecule that can compensate for defective β-globin. 'Potential for more efficient editing and promising efficacy data,' one physician noted, adding that Casgevy's 'novel CRISPR platform' and accumulating real-world experience were compelling advantages. Zynteglo (betibeglogene autotemcel, bluebird bio) takes a different approach: inserting a functional HBB (β-globin) gene into a patient's hematopoietic stem cells via a lentiviral vector, restoring normal hemoglobin production. Physicians highlight its 'higher rate of transfusion independence (90–95% in long-term studies),' 'well-established safety profile,' and 'durable results' as support for their preference. While some clinicians see Casgevy as a leap forward in precision and efficiency, others value Zynteglo's longer track record and direct β-globin restoration. For many, the choice remains personalized, depending on patient genotype, treatment center expertise, insurance coverage, and patient or family comfort with each technology. Despite the promise of both therapies, physicians in suburban and rural areas report that demand for gene therapy exceeds available capacity. In addition, hematologists in the south and west are more likely to cite physical distance to certified gene therapy centers as a barrier. Even when centers are accessible, high upfront costs, lengthy insurance approvals, and constrained treatment slots can delay care. TDT is a severe inherited blood disorder requiring lifelong blood transfusions and iron chelation therapy. Gene therapy offers the potential for transfusion independence, but equitable access remains a critical challenge. Spherix will continue to monitor the hemoglobinopathy market, including thalassemia, through annual Market DynamixTM and Patient Chart DynamixTM services. Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. Patient Chart Dynamix™ is an independent service that includes robust patient chart audits and integrated specialist surveys fielded biannually. This research provides an in-depth, real-world view of treatment practices by combining verified patient data with attitudinal insights from physicians. The series highlights clinical decision-making, treatment sequencing, and outcomes for targeted patient populations across key therapeutic areas. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: Spherix Global Insights Contacts Sarah Hendry, Hematology Franchise Head NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284
New York Post
an hour ago
- New York Post
Costco won't sell abortion pills after outcry from religious groups
Costco said it will not offer abortion pills at any of its more than 500 pharmacies nationwide, a move celebrated by religious groups that lobbied against the drug being dispensed by retailers. The Washington state-based wholesaler insisted its decision was based on a lack of customer interest in the medication, Mifepristone, which together with another medicine called misoprostol, is used to end a pregnancy within 10 weeks of gestation. It didn't address whether pressure from conservative organizations influenced the move. 4 A Costco location in the US, one of more than 500 company pharmacies that will not provide Mifepristone. Getty Images A coalition of religious groups including Idaho-based Inspire Investing, the conservative legal organization Alliance Defending Freedom and treasurers and other financial officials from Ohio, Texas, Nevada and Utah had contacted the retailer last year requesting it not carry the drug, according to Bloomberg News. 'It's a very significant win and it's one we hope to build on this coming year,' said Michael Ross, an attorney working with Alliance Defending Freedom's corporate engagement division. Ross indicated the coalition plans to target Walgreens Boots Alliance and CVS next. Both pharmacy chains currently provide mifepristone in states that don't have abortion restrictions. People living in states that have severely limited abortion can obtain the medication by mail from states without such bans. The religious investors sent similar requests last year to Kroger, Walmart and Albertsons alongside Costco, urging them against carrying the medication. Kroger responded that it has never provided abortion pills and continues monitoring regulatory developments. Neither Walmart nor Albertsons currently stocks the medicine. Costco's decision intensifies the ongoing debate about access to the medication. 4 Mifepristone tablets are part of a two-drug regimen to terminate early pregnancies. AP New York City Comptroller Brad Lander had written to various retailers in July last year representing city pension funds, encouraging them to pursue authorization for offering the drug. 'Costco's decision to refuse to dispense mifepristone is disappointing and short-sighted,' a representative from Lander's office told Bloomberg. 'Failure to provide access to proven safe and FDA-approved medication under the guise of 'weak demand' risks isolating customers and undermines the company's credibility.' The Post has sought comment from Costco and Lander. The religious organizations have promised to continue to ramp up pressure. 'We have this momentum,' said Tim Schwarzenberger, who leads corporate engagement at Inspire, which manages the biggest religious exchange-traded fund. 'Now there is a chance to turn to some of the other retailers.' doesn't presently sell the medication, and Schwarzenberger indicated his organization will work to maintain that status. 4 A patient prepares to take mifepristone, which blocks progesterone to end an early-stage pregnancy. AP Amazon didn't provide a response to inquiries. Walgreens declined to comment but referenced information on its website stating: 'The US Supreme Court's ruling on mifepristone access allows Walgreens to continue to dispense mifepristone under the FDA guidelines.' CVS confirmed it distributes mifepristone in certain states where permitted after completing what it called a thorough certification procedure. 'We have a long history of supporting and advancing women's health and we remain focused on meeting their unique health needs. This includes providing access to safe, legal, and evidence-based reproductive health services,' the company stated. The elimination of nationwide abortion protections has resulted in uneven access throughout the US, leading telehealth providers to address some service gaps. Various state legislators have proposed legislation to designate mifepristone as a restricted drug and reduce telehealth availability. According to tracking by the Guttmacher Institute, a nonprofit research organization, lawmakers introduced 32 proposals to prohibit medication abortion and 38 to restrict access during the 2025 legislative period, representing the highest number since the overturn of Roe v. Wade. Data from the Society of Family Planning, an abortion rights organization, shows most abortions in America still occur either at medical facilities or through prescriptions from doctors filled at pharmacies like CVS or Walgreens. A smaller percentage involves prescriptions delivered by mail. 4 Anti-abortion demonstrators rally outside the US Supreme Court in March of last year as debate over medication abortion continues. AP Following increased state-level abortion restrictions, more women have pursued online mifepristone prescriptions for mail delivery. These shipments now represent approximately 25% of American abortions, up from 5 percent before the 2022 Supreme Court decision that ended federal abortion protections. Eight states permitting abortion have enacted protective legislation shielding doctors from prosecution when prescribing mifepristone to patients in states with abortion prohibitions. Ushma Upadhyay, a reproductive sciences professor at the University of California, San Francisco, explained that CVS, Walgreens and similar pharmacies don't provide the medication in states prohibiting abortion, creating difficulties for women seeking the procedure. Telehealth providers can utilize protective laws to ship pills directly to states with restrictions, she noted. This has generated legal disputes. A Texas resident filed a lawsuit in July against a California physician for prescribing abortion medication to his girlfriend. A New York doctor faces criminal charges in Louisiana and a lawsuit from Texas's Attorney General for shipping pills to patients in those states.
